Medicine & Life Sciences
Melanoma
100%
pembrolizumab
70%
Belgium
64%
Coronavirus
62%
Dendritic Cells
56%
Ipilimumab
52%
HIV
48%
Therapeutics
46%
Nivolumab
44%
Clinical Trials, Phase I
40%
avelumab
39%
trametinib
34%
dabrafenib
33%
HIV-1
32%
Neoplasms
30%
Islets of Langerhans
29%
Glioblastoma
28%
Type 1 Diabetes Mellitus
28%
trimix
28%
Safety
27%
Myeloid Cells
26%
Phase II Clinical Trials
25%
T-Lymphocytes
25%
Survival
23%
Vaccines
23%
Tumor Burden
22%
Brugada Syndrome
22%
Immunotherapy
22%
Thyroid Gland
21%
Clinical Trials
20%
Axitinib
19%
Systematic Reviews
18%
Renal Replacement Therapy
18%
Fluorodeoxyglucose F18
18%
Messenger RNA
17%
Infection
17%
HIV Infections
17%
Lactams
17%
Mitogen-Activated Protein Kinase Kinases
17%
Hemofiltration
16%
Cohort Studies
15%
Standard of Care
15%
Anti-Bacterial Agents
15%
Recurrence
15%
Population
14%
Retrospective Studies
14%
Pharmaceutical Preparations
14%
Severe Acute Respiratory Syndrome
13%
Vaccination
13%
Cardiac Arrhythmias
13%
Pancreas
13%
Frailty
13%
Biomarkers
13%
Transplants
13%
Non-Small Cell Lung Carcinoma
12%
Neoplasm Metastasis
12%
Ventilator-Associated Pneumonia
12%
Familial Hypophosphatemic Rickets
12%
Antibodies
12%
Observational Studies
12%
Activities of Daily Living
12%
Tsunamis
12%
Fever
12%
Programmed Cell Death 1 Receptor
12%
Blocking Antibodies
12%
Liver
12%
Injections
12%
Skin
11%
dicarboxydine
11%
Peptides
11%
Cytokines
11%
Fatigue
11%
Incidence
11%
Immunologic Monitoring
11%
Progression-Free Survival
11%
Autoimmunity
11%
Atrial Fibrillation
10%
Lymphoma
10%
Viruses
10%
Cell Death
10%
Delivery of Health Care
10%
Echocardiography
10%
SARS Virus
10%
AIDS Vaccines
10%
Hypophysitis
10%
Insulin
10%
Parathyroid Neoplasms
10%
Serum
10%
Adrenocorticotropic Hormone
10%
Omentum
9%
Critical Illness
9%
Pituitary Neoplasms
9%
Public Health
9%
Meta-Analysis
9%
Hypertension
9%
Monoclonal Antibodies
9%
Delirium
9%
IGL-1 solution
9%
Autoantibodies
9%
Survivors
9%